Dr. Philippe Prokocimer
Chief Medical Officer
AntiBioTX
Denmark
Biography
Dr. Philippe Prokocimer, M.D. is the Chief Medical Officer of AntibioTx. Dr. Prokocimer was Officer of Trius Therapeutics from July 2007 until its acquisition by Cubist in 2014. At Cubist, Dr. Prokocimer became Senior Vice President of Clinical Development until the acquisition by Merck in January 2015. At Merck, he became Associate Vice President of Clinical Development, Head of San Diego site. Dr. Prokocimer has been developing anti-infective drugs for 30 years and has been involved with successful approval of 6 New Drug Applications including 5 antibiotics: Doripenem (Doribax®), Quinupristin/dalfopristin (Synercid®), Sparfloxacin (Zagam®), Clarithromycin (Biaxin®) and Tedizolid Phosphate (Sivextros®). Dr. Prokocimer received an M.D. degree from the School of Medicine in Paris, France and a Post-Doctoral Research Fellowship from Stanford University.
Research Interest
Management
